Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
  • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
  • C12N9/6489—Metalloendopeptidases (3.4.24)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/90—Isomerases (5.)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Definitions

• the present invention relates to novel polypeptides and their use for the in vitro evaluation of the sensitizing potential of a test compound, to a method for in vitro evaluation of the sensitizing potential of a test compound, to an in vitro method for the selection of a compound capable of decreasing sensitization, as well as kits for the implementation of such methods.
• NGAL neurotrophil gelatinase associated lipocalin
• SEO et al Expression of neutrophil gelatinase-associated lipocalin in epidermis skin, J.
• NGAL was originally identified as a 25kDa protein covalently associated with the 92kDa "neutrophil gelatinase" (or gelatinase B, MMP-9). Crystallographic analysis has shown that the natural ligands of this enzyme are a variety of bacterial ferric siderophores thus acting as a bacteriostatic. In the kidney, this enzyme plays the same role in delivering iron into the cells of the nephron. NGAL is induced by calcium in cultured keratinocytes and its presence in human and murine skin has been confirmed, particularly in the epidermis (in keratinocytes only) and hair follicles, by in situ hybridization.
• L-PGDS whose role originally described is to isomerize prostaglandin H2 to prostaglandin D2, also functions as a lipophilic protein of the spaces extracellular whose known ligands are bilirubin, retinaldehyde and retinoic acid. Recent studies have shown that L-PGDS is present in Langerhans cells, melanocytes, mast cells, histiocytes and macrophages (but not in keratinocytes) in the rat.
• the inventors then identified particular sequences of these lipocalins or derived from them, for the development of in vitro evaluation methods of the sensitizing potential of compounds likely to behave as allergens.
• the present invention relates to an isolated polypeptide comprising a sequence selected from the sequence SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 and derivatives thereof.
• an isolated polypeptide comprising a sequence chosen from the sequence SEQ ID NO: 1, 2, 3, and 4, still more preferably an isolated polypeptide comprising the sequence SEQ ID NO: 1 or the sequence SEQ ID NO : 3, and more preferably an isolated polypeptide comprising the sequence SEQ ID NO: 1.
• ECGX1DELX2EX3 (SEQ ID NO: 3)
• LYSRSQNPRAEVX1EHFTTFAX2SLGFTEE (SEQ ID NO: 6)
• X1, X2, X3 and X4 are independently selected from lysine, ornithine, diaminobutyrate or diaminopropionate, preferably lysine.
• each of the groups X1, X2, X3 and X4 each represents a lysine.
• X1, X2, X3 and X4 each represent a lysine group, and thus corresponds to the following sequence SEQ ID NO: 20: KACAKDELKEK (SEQ ID NO: 20) .
• said sequence SEQ ID NO: 20 has an amino group (NH 2) at its C-terminal end.
• sequence SEQ ID NO: 2 X1, X2, X3 and X4 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 21: KEKLEDKACAK (SEQ ID NO: 21)
• sequence SEQ ID NO: 3 X1, X2 and X3 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 22: ECGKDELKEK (SEQ ID NO: 22)
• sequence SEQ ID NO: 4 X1, X2 and X3 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 23:
• sequence SEQ ID NO: 5 X1, X2 and X3 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 24:
• X1 and X2 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 25:
• sequence SEQ ID NO: 7 X1, X2, X3 and X4 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 26: LYGRTKELSPELKERFTFAKSLGLK (SEQ ID NO: 26) .
• X1, X2, X3 and X4 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 27: LYSRTQTLKDELKEKFTTFSKAQGLT (SEQ ID NO: 27) .
• X1 represents a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 28: RQNQCETK (SEQ ID NO: 28)
• X1 represents a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 29: TLYGRTKEL (SEQ ID NO: 29)
• sequence SEQ ID NO: 11 X1 and X2 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 30:
• sequence SEQ ID NO: 12 X1, X2 and X3 each represent a lysine group, and the sequence thus corresponds to the following sequence SEQ ID NO: 31: KEKFTTFSK (SEQ ID NO: 31)
• X1 represents a lysine group
• sequence SEQ ID NO: 32 LYGRTKELS (SEQ ID NO: 32)
• sequences SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 may have an acetyl group at their N-terminal end.
• sequences SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 may have an amino group (NH 2) or amide (C0NH 2) at their C-terminus - Terminal.
• sequences SEQ ID NO: 1 SEQ ID NO: 3 have an amine or amide group at their C-terminal end.
• Said polypeptide isolated according to the present invention may be in the L form or in the D form.
• the polypeptides according to the present invention have a length of less than 100 amino acids, preferably less than 80, more preferably less than 50, more preferably less than 40 and most preferably less than 50. any less than 30 amino acids.
• derivatives is meant a polypeptide having one or more sequence mutations not modifying the activity of said polypeptide, in particular a polypeptide having one or more so-called 'conservative' mutations and mutations not affecting the thiol pKa values. of the cysteine and / or lysine residue and / or having an identity percentage of at least 80% with the complete sequence of the sequence SEQ ID NO: 1 to 13, preferably at least 90%, and still more preferably at least 95%.
• conservative mutation is meant a mutation selected from substitution of a basic amino acid residue with another basic amino acid residue, an acidic amino acid residue with another amino acid residue. acid, a neutral amino acid residue with another neutral amino acid residue, an aliphatic amino acid residue with another aliphatic or aromatic amino acid residue, an amino acid residue aromatic by another aromatic or aliphatic amino acid residue, an amino acid residue amidated by another amide amino acid residue, an alcoholic amino acid residue by another alcoholic amino acid residue .
• percent identity between two amino acid sequences, the identical amino acid percentages between the two sequences to be compared, obtained with the best alignment of said sequences, this percentage being purely statistical and the differences between the two sequences being randomly distributed in the amino acid sequences.
• “Better alignment” is the alignment for which the percentage of identity is highest. The sequence comparison between two amino acid sequences is generally performed by comparing these previously aligned sequences according to the best alignment; this comparison is performed on comparison segments in order to identify and compare the similarities of regions.
• the percentage identity between two amino acid sequences is determined by comparing these two sequences. optimally aligned, the amino acid sequences may include additions or deletions relative to the reference sequence to achieve optimal alignment between the two sequences. The percent identity is calculated by determining the number of identical positions between the two sequences, and dividing that number by the total number of positions compared, and multiplying that number by one hundred.
• said isolated polypeptide consists of a sequence chosen from the sequence SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 and derivatives of these, preferably in a sequence selected from the sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and derivatives thereof, preferably in a sequence chosen from the sequence SEQ ID NO: 1 and SEQ ID NO: 3, even more preferably in the sequence SEQ ID NO: 1.
• the isolated polypeptide consisting of the sequence SEQ ID NO: 1, and still more preferably in the sequence SEQ ID NO: 20, is particularly preferred because its synthesis and purification are easy, it has excellent solubility and is easy to handle because it is not very electrostatic. it is only very slightly dimerized, which facilitates its use in the methods according to the present invention, and finally it makes it possible to detect the allergens fixed on said sequence in a single reaction step.
• the present invention relates to a nucleotide sequence comprising a nucleic acid sequence encoding a polypeptide as defined above.
• the nucleotide sequence according to the present invention may be in the form of RNA or DNA, preferably in the form of DNA.
• Said DNA may be in double-stranded or single-stranded form.
• the present invention relates to a method for in vitro evaluation of the sensitizing potential of a test compound, comprising the steps of: a) contacting a test compound with an isolated polypeptide comprising a selected sequence among SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17 and derivatives thereof; b) measuring the possible binding of said test compound with said polypeptide.
• the evaluation method may also be performed ex vivo.
• sequence SEQ ID NO: 14 represents the polypeptide sequence of human lipocalin 2:
• sequence SEQ ID NO: 15 represents the polypeptide sequence of mouse lipocalin 2:
• sequence SEQ ID NO: 16 represents the polypeptide sequence of human prostaglandin D synthase:
• sequence SEQ ID NO: 17 represents the polypeptide sequence of mouse prostaglandin D synthase: MAALRMLWMGLVLLGLLGFPQTPAQGHDTVQPNFQQDKFLGRWYSAGLASNSS WFREKKAVLYMCKTVVAPSTEGGLNLTSTFLRKNQCETKIMVLQPAGAPGHYTY SSPHSGSIHSVSVVEANYDEYALLFSRGTKGPGQDFRMATLYSRTQTLKDELKEKF TTFSKAQGLTEEDIVFLPQPDKCIQE (SEQ ID NO: 17)
• one or more of the lysine residues of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17 may be replaced by ornithine, diaminobutyrate or diaminopropionate.
• the isolated polypeptide comprises a sequence selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 and derivatives thereof.
• the measurement of the possible binding obtained in step b) may optionally be compared with a negative control carried out in the absence of the test compound or in the presence of a compound known as non-sensitizing, such as for example chlorobenzene (Cbz) or lactic acid (LA), or to a positive control carried out with a known ligand of said polypeptide.
• a compound known as non-sensitizing such as for example chlorobenzene (Cbz) or lactic acid (LA)
• said method according to the present invention may further comprise a step c) of determining the sensitizing potential of a test compound. The higher the binding percentage, the greater the sensitizing potential.
• Said bond may for example be a covalent bond, hydrogen, saline, electrostatic, Van der Waals, a radical attack ...
• said bond is a covalent bond.
• the measurement of the bond can be carried out by any measurement technique of a bond well known to those skilled in the art.
• a labeling which may be of antigenic, fluorescent, enzymatic or radioactive type, a separation by liquid chromatography (HPLC), the use of surface plasmon resonance technique, etc.
• the polypeptide is linked to an antigenic marker and the measurement of the binding of said test compound with said polypeptide is carried out by means of a detectable antibody directed against said antigenic marker.
• This antigenic marker can be any type of marker known to those skilled in the art and can be chosen in particular from a polyhistidine amino acid sequence (polyHis), a cMyc element, Flag or an isolated sequence of haemagglutinin or the V5 protein.
• the polyHis sequence preferably contains from 4 to 6 Histidine residues.
• the antigenic marker is a polyhistidine amino acid sequence (polyHis).
• the antibodies used to detect this antigenic marker may be polyclonal or monoclonal. They can be produced by conventional techniques known to those skilled in the art. These may be commercial antibodies. Among these, mention may be made of the penta-His HRP conjugate antibody (QIAGEN), the anti-6x His rabbit antibody Abcam 9108, the HRP-labeled horseradish-6x His rabbit antibody (horseradish peroxidase), and Abcam. 1187, mouse antibody -anti-5x His Qiagen 34698, mouse antibody -anti-poly-His Sigma H-1029.
• Antibodies can be coupled to detectable markers known to those skilled in the art, such as enzymes (eg HRP horseradish peroxidase), radioactive labels, fluorescers, magnetic particles, and the like.
• enzymes eg HRP horseradish peroxidase
• radioactive labels eg HRP horseradish peroxidase
• fluorescers eg. fluorescers, magnetic particles, and the like.
• the antibody is coupled to HRP (HorseRadish Peroxidase).
• the immunodetection can be carried out by any suitable technique, for example a Western Blot, Dot Blot, etc.
• the polypeptide is linked to a fluorescent label and the measurement of the binding of said test compound with said polypeptide is carried out by fluorometry.
• the fluorescent labeling may be direct or indirect, the fluorophore being attached directly to the polypeptide or via another marker.
• the fluorescent label may be, for example, fluorescein, RPE (R-Phycoerythrin), GFP (Green Fluorescent Protein), APC (AlloPhycoCyanin), cyanines or Europium.
• polypeptide is linked to an enzyme label and the measurement of the binding of said test compound with said polypeptide is by fluorometry, luminescence or colorimetry, depending on the substrate used in the enzymatic reaction.
• the measurement of the binding of said test compound with said polypeptide can in particular be carried out using a colorimetric substrate (p-Nitrophenyl Phosphate or pNPP), fluorescent (Fluorescein Diphosphate or FDP) or luminescent (Lumi-Phos TM), the measured the interaction is then carried out respectively by spectrophotometry at 405 nm, by fluorimetry (exitation: 485 nm, emission: 535 nm) or by luminescence.
• a colorimetric substrate p-Nitrophenyl Phosphate or pNPP
• fluorescent Fluorescein Diphosphate or FDP
• luminescent Li-Phos TM
• the polypeptide may be attached to a support.
• the support preferentially used for the implementation of the method according to the present invention is a plate, a ball or a chip.
• polypeptides used in the method according to the present invention may be prepared by any technique known to those skilled in the art, in particular by artificial synthesis and more particularly by solid phase synthesis.
• test compound may be a compound of varied nature, structure and origin, including a biological compound, a chemical compound, synthetic compound, etc.
• the test compound can be any product that is in an isolated form or in admixture with other products.
• the test compound can be defined in terms of structure and / or composition or be defined functionally.
• the test compound may, for example, be an isolated and structurally defined product, an isolated product of indefinite structure, a mixture of known and characterized products or a composition comprising one or more products.
• One or more compounds can thus be tested, in admixture or separately.
• compositions may be, for example, samples of a cosmetic or dermatological product.
• the test compound may be of natural or synthetic origin.
• the present invention is particularly suitable for the identification of a large number of compounds. This simple and efficient screening can be accomplished in a very short time.
• the described methods can be partially automated, thus enabling efficient and simultaneous screening of various and diverse compounds, either as a mixture or in separate form.
• the method according to the invention is carried out in HTS (High Throughput Screening) or in MTS (Medium Throughput Screening).
• polypeptide means a sequence comprising at least two amino acids, and the terms “polypeptide”, “peptide” and “protein” may be used interchangeably.
• sensitizing potential means the risk for the test compound of causing an immunological reaction when it is brought into contact with a mammal, preferably a human.
• the sensitizing potential can be considered as the risk of developing an allergy in contact with the test compound.
• said test compound is capable of being applied to the skin.
• the sensitizing potential corresponds to the risk of developing a skin allergy.
• said test compound is capable of entering into the composition of a dermatological or cosmetic composition.
• the method according to the present invention makes it possible to evaluate whether the test compound is likely to cause a contact allergy or atopic dermatitis.
• the method according to the present invention is carried out in a buffer solution having a pH of between 7.3 and 9.3, more preferably between 7.8 and 8.8, and particularly preferably the buffer solution having a pH of 8.3.
• the method according to the present invention is carried out at a temperature of between 20 ° C. and 40 ° C., more preferably between 25 ° C. and 35 ° C., more preferably between 28 ° C. and 32 ° C., and most preferably at 30 ° C.
• the method according to the present invention is carried out in the dark.
• the concentration of polypeptide used for carrying out the method according to the present invention is between 0.2 and 1.5 mM, more preferably between 0.4 and 1.2 mM, more preferably 1 mM.
• the concentration of the test compound for carrying out the process according to the present invention is between 1 and 10 mM, more preferably between 3 and 7 mM, more preferably between 4 and 6 mM and preferably between any of 5mM.
• the test compound can be contacted with several isolated polypeptides having different sequences.
• the evaluation method according to the present invention may be a competition test, in which the test compound competes with a compound identified as a sensitizer. Said compound identified as sensitizer may be brought into contact with said polypeptide isolated prior to step a), or simultaneously with step a). Such an embodiment makes it possible to compare the sensitizing potential of a test compound with that of a compound identified as a sensitizer.
• the present invention relates to an in vitro method for selecting a compound capable of decreasing sensitization, comprising the steps of: a) contacting a compound identified as a sensitizer with a polypeptide isolated compound comprising a sequence selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17 and derivatives thereof and a candidate compound to decrease sensitization; b) measuring the possible binding of the compound identified as sensitizing with said polypeptide.
• Said method for the selection of a compound capable of reducing the sensitization can be carried out under the same conditions as those described above for the in vitro evaluation method of the sensitizing potential of a test compound.
• compound capable of decreasing sensitization means a compound capable of reducing the sensitizing potential of a compound identified as a sensitizer.
• compound capable of decreasing sensitization means a compound which reduces the risk of causing an immunological reaction in the presence of a compound identified as a sensitizer.
• desensitizing compound may also be used to define the "compound capable of decreasing sensitization”.
• a compound is capable of reducing the sensitization if it makes it possible to reduce the sensitizing potential of a compound identified as sensitizer by at least 10%, preferably by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and preferably 100% relative to the sensitizing potential observed in the absence of said desensitizing compound.
• the term "compound identified as sensitizer” means a compound that can be identified by the method of the present invention, ie, in other words, a compound identified as having an allergenic potential.
• the compound that can be identified by means of the method according to the invention can be a compound of varied nature, structure and origin, in particular a biological compound, a chemical compound, synthetic compound, etc.
• the compound identified as sensitizer is selected from diphenylcyclopropenone (DPCP), lauryl gallate (LG), 3-3-dimethylaminopropylamine
• 3-DMAPA cinnamic aldehyde (CA), citral (Cal), 1,4-hydroquinone (HQ), glutaraldehyde (GA), 1,2-benzisothiazolin-3-one (Ben), phenylacetaldehyde (PA) and lilial (Li), preferably from diphenylcyclopropenone, lauryl gallate, 1,4-hydroquinone and glutaraldehyde, and particularly preferably diphenylcyclopropenone.
• Diphenylcyclopropenone is an extremely strong sensitizer; lauryl gallate, 1,4-hydroquinone and glutaraldehyde are strong sensitizers; 3-3-dimethylaminopropylamine, cinnamaldehyde, citral, 1,2-benzisothiazolin-3-one and phenylacetaldehyde are moderate sensitizers, and the ilium is a weak sensitizer.
• the candidate compound for decreasing sensitization may be any product which is in isolated form or in admixture with other products.
• the candidate compound for decreasing sensitization can be defined in terms of structure and / or composition or be functionally defined.
• the candidate compound for decreasing sensitization can, for example, be an isolated and structurally defined product, an isolated product of indefinite structure, a mixture of known and characterized products or a composition. comprising one or more products. One or more compounds can thus be tested, in admixture or separately.
• the test compound may be of natural or synthetic origin.
• the ability of a candidate compound to decrease or inhibit binding can be evaluated by comparing the binding capacity of a polypeptide comprising at least one sequence selected from SEQ ID NO: 1, 2, 3, 4, 5 , 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17 and derivatives thereof, with a compound identified as sensitizing in the presence of said candidate compound, to the binding capacity of said polypeptide with said compound identified as a sensitizer in the absence of said candidate compound.
• a decrease or inhibition of the binding capacity is observed in the presence of said candidate compound, it can be concluded that said candidate compound is a compound capable of reducing the sensitization.
• said candidate compound is suitable for use on the skin and can be used in a cosmetic or dermatological composition.
• Step a) may be carried out: i) by first contacting the compound identified as sensitizer and isolated polypeptide as defined above, optionally followed by a first measurement of the binding of the compound identified as sensitizing with said isolated polypeptide, then contacted with the candidate compound to decrease the sensitization with the compound identified as a sensitizer bound to the isolated polypeptide; ii) by contacting the compound identified as a sensitizer with the candidate compound beforehand to reduce the sensitization and then bringing the isolated polypeptide as defined above into contact with the compound identified as sensitizing agent and the candidate compound for reducing the sensitization; or iii) by simultaneously bringing into contact the compound identified as sensitizing agent, the candidate compound to reduce the sensitization and the isolated polypeptide as defined above.
• the isolated polypeptide comprises a sequence selected from SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 and derivatives thereof.
• the present invention also relates to a kit for the implementation of an in vitro evaluation method of the sensitizing potential of a test compound according to the present invention, comprising at least one isolated polypeptide comprising a sequence chosen from SEQ sequences. ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17 and derivatives thereof.
• said isolated polypeptide comprises a sequence selected from the sequences SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 and derivatives thereof, preferentially among the sequences SEQ ID NO: 1, 2, 3, 4, and even more preferably among the sequences SEQ ID NO: 1 and SEQ ID NO: 3.
• the present invention also relates to a kit for implementing a method for selecting compounds capable of reducing the sensitization according to the present invention, said kit comprising at least one polypeptide comprising a sequence chosen from the sequences SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17 and derivatives thereof, and at least a compound identified as sensitizer.
• the compound identified as a sensitizer is chosen from diphenylcyclopropenone, lauryl gallate, 3-3-dimethylaminopropylamine, cinnamaldehyde, citral, 1,4-hydroquinone, glutaraldehyde, 1,2-benzisothiazolinol 3- one, phenylacetaldehyde and lilial, preferably from diphenylcyclopropenone, lauryl gallate, 1,4-hydroquinone and glutaraldehyde, and particularly preferably is diphenylcyclopropenone.
• said isolated polypeptide comprises a sequence selected from the sequences SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 and derivatives thereof, preferentially among the sequences SEQ ID NO: 1, 2, 3, 4, and even more preferably among the sequences SEQ ID NO: 1 and SEQ ID NO: 3.
• the present invention relates to the use of a polypeptide comprising a sequence chosen from the sequences SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16 and 17 and derivatives thereof for the in vitro evaluation of the sensitizing potential of a test compound.
• said isolated polypeptide comprises a sequence selected from the sequences SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 and derivatives thereof, preferentially among the sequences SEQ ID NO: 1, 2, 3, 4, and even more preferably among the sequences SEQ ID NO: 1 and SEQ ID NO: 3.
• test with 0.5 mM of polypeptide and 5 mM of test compound was carried out under the following conditions:
• X1, X2, X3 and X4 are independently selected from lysine, ornithine, diaminobutyrate or diaminopropionate, and at least one of Xl, X2, X3 and X4 is not lysine.
• a high percentage of lauryl gallate binding which has a strong sensitizing power is observed for the 3 sequences studied, a high percentage of cinnamaldehyde aldehyde binding, which has a moderate sensitizing power, for the sequence SEQ ID NO: 7 and moderate for the sequences SEQ ID NO: 8 and SEQ ID NO: 18.
• test with 0.5 mM of polypeptide of sequence SEQ ID NO: 29 and 5 mM of test compound was carried out according to the same protocol as that described for Example 1.
• sequence SEQ ID NO: 19 which is not a lipocalin derivative, served as a positive control. This sequence corresponds to the following sequence:
• AC-RFAACAA-NH 2 (SEQ ID NO: 19)
• the buffer used was 10mM TRIS-HCl at pH8.3.
• fixation indicates that a fixation exists, but that it is not quantifiable.
• n / a non-determinable fixation at an identical retention time.
• X1, X2, X3 and X4 are independently selected from lysine, ornithine, diaminobutyrate or diaminopropionate, and at least one of Xl, X2, X3 and X4 is no lysine.
• the buffer used was TRIS-HCl. 10OmM.
• X1, X2, X3 and X4 are independently selected from lysine, ornithine, diaminobutyrate or diaminopropionate, and at least one of Xl, X2, X3 and X4 is not lysine.
• the signal was disturbed, preventing measurements greater than 82-83% fixation. These values therefore represent a minimum.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Organic Chemistry (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• General Engineering & Computer Science (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Physics & Mathematics (AREA)
• Cell Biology (AREA)
• Food Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=41319632

Family Applications (1)

Country Status (7)

Families Citing this family (5)

Citations (1)

Family Cites Families (6)

• 2009
  • 2009-04-30 FR FR0952929A patent/FR2945042B1/fr not_active Expired - Fee Related
• 2010
  • 2010-04-30 JP JP2012507778A patent/JP2012525131A/ja active Pending
  • 2010-04-30 BR BRPI1014622-9A patent/BRPI1014622A2/pt not_active IP Right Cessation
  • 2010-04-30 CA CA2760685A patent/CA2760685A1/fr not_active Abandoned
  • 2010-04-30 EP EP10715868A patent/EP2424983A1/de not_active Withdrawn
  • 2010-04-30 US US13/318,064 patent/US8703431B2/en not_active Expired - Fee Related
  • 2010-04-30 WO PCT/EP2010/055895 patent/WO2010125176A1/fr active Application Filing

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events